Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Fig. 5

Mitochondrial ROS in EP13-treated cells. MDA-MB-231 (a, b) and MCF-7 (c, d) cells were treated for 4 or 24 h with vehicle or EP13 (6 μM). At the end of treatment, the cells were incubated in the presence of 5 µM MitoSOX™ Red fluorescent probe and analysed by flow cytometry. e MDA-MB-231 cells were treated for 48 h with H2O2 (50 µM) or EP13 (6 µM) in the presence or absence of the antioxidant NAC (1 mM). The results are depicted as the mean ± SEM of at least three independent measurements. Significant differences from control cells are indicated (*, p < 0.05; **, p < 0.01; ns, non significant)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us